Clients and testimonials

Always aiming at high quality services coupled to true customer focus, Biomedcode has built its reputation steadily over the years gaining the trust and respect of its clients. Since its establishment, Biomedcode has attracted clients from Europe, the United States, Asia and Australia some of them ranked among the top 5 pharmaceutical companies worldwide. Preclinical data generated following our successful collaboration with our clients, have been incorporated in IND applications for FDA, SFDA & EMEA approval.

Our clients publish

  • Biesemann N, Margerie D, Asbrand C, Rehberg M, Savova V, Agueusop I, Klemmer D, Ding-Pfennigdorff D, Schwahn U, Dudek M, Heyninck K, De Tavernier E, Cornelis S, Kohlmann M, O Nestle F, Herrmann M.2023. Additive efficacy of a bispecific anti-TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis Sci Transl Med 15(681):eabq4419. PMID: 36724239.
  • Ishiwatari-Ogata C, Kyuuma M, Ogata H, Yamakawa M, Iwata K, Ochi M, Hori M, Miyata N and Fujii Y. 2022. Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG. Front. Immunol 13 - 2022 |
  • Yun-Chi Lu, Chih-Hung Chuang, Kuo-Hsiang Chuang, I-Ju Chen, Bo-Cheng Huang, Wen-Han Lee, Hsin-Ell Wang, Jia-Je Li, Yi-An Cheng, Kai-Wen Cheng, Jaw-Yuan Wang, Yuan-Chin Hsie, Wen-Wei Lin, Tian-Lu Cheng. 2019. Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy. PLoS Biol 17(6):e3000286. PMID: 31194726.
  • Obinna C Ubah, John Steven, Andrew J Porter, Caroline J Barelle.2019 An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model. Front Immunol 10:526. PMID: 30967865.
  • Moore A, Allden S, Bourne T, Denis MC, Kranidioti K, Okoye R, Sotsios Y, Stencel Z, Vugler A, Watt G, et al. 2014. Collagen II antibody-induced arthritis in Tg1278TNFko mice: optimization of a novel model to assess treatments targeting human TNFα in rheumatoid arthritis. J Transl Med 12(1):285. PMID: 25344414.

UCB Celltech & Biomedcode co-author a  paper demonstrating that CAIA in the human TNF transgenic (Tg1278TNFko) mice is a well-suited animal model for testing the next generation of therapeutics targeting human TNFα in rheumatoid arthritis.

  • Kanakaraj P, Puffer BA, Yao XT, Kankanala S, Boyd E, Shah RR, Wang G, Patel D, Krishnamurthy R, Kaithamana S, Smith RG, LaFleur DW, Barbas CF 3rd, Hilbert DM, Kiener PA, Roschke VV, 2012. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs. 4(5):600-13. PMID:22864384.

Biomedcode’s Tg197 transgenic model of rheumatoid arthritis was used to  test the efficacy of various anti-TNF antibodies.

  • Maity S, Ullanat R, Lahiri S, Shekar S, Sodhan G, Vyas A, Dyaga G, Ireni S, Nair N, Sotsios Y, Denis MC, Morawala-Patell V, 2011 . A non-innovator version of etanercept for treatment of arthritis. Biologicals. 39(6):384-95. PMID: 21996051.
  • Gay RD, Clarke AW, Elgundi Z, Domagala T, Simpson RJ, Le NB, Doyle AG, Jennings PA, 2010. Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size. MAbs, 2(6):625-38.. PMID20930515.

A publication on a novel antibody characterization where the experiments were performed using Tg197 transgenic mouse model by Biomedcode.